San Diego, California, August 13, 2026
Atrium Therapeutics, Inc. announced that it has earned a $15 million milestone payment from Bristol Myers Squibb (BMS) under their global licensing and research collaboration focused on developing RNA-based therapies for cardiovascular diseases. The payment was triggered by the successful delivery of a lead compound targeting an undisclosed cardiology indication. The milestone marks continued progress in the collaboration and highlights Atrium’s efforts to develop targeted RNA therapeutics designed to address the underlying drivers of serious heart diseases.
Atrium Advances RNA Therapeutics for Heart Disease
Atrium Therapeutics is focused on developing targeted RNA medicines for cardiovascular diseases, with an emphasis on delivering therapeutic molecules directly to the heart. The company’s proprietary delivery approach combines the tissue selectivity of monoclonal antibodies and other targeted delivery ligands with the precision of oligonucleotide therapeutics, including small interfering RNA (siRNA). The platform is designed to enable targeted, non-viral delivery of RNA medicines to cardiac tissue and potentially address genetically driven diseases at their underlying molecular source. The latest milestone follows the successful delivery of a second lead compound under the ongoing BMS collaboration. Atrium said the progress demonstrates the versatility of its RNA delivery platform and provides continued momentum for the development of potential therapies for patients with significant unmet cardiovascular needs. The collaboration covers the discovery, development and commercialization of innovative RNA-based therapies across multiple cardiovascular indications.
BMS Collaboration Includes Major Milestone Potential
Under the terms of the global collaboration, Atrium is eligible to receive up to approximately $1.35 billion in research and development milestone payments, in addition to up to approximately $825 million in commercial milestone payments. Atrium is also eligible for tiered royalties reaching the low double digits on net sales of products arising from the collaboration. Bristol Myers Squibb will fund future clinical development, regulatory and commercialization activities associated with programs generated through the collaboration. The newly earned $15 million payment represents another development milestone within this broader strategic relationship. Delivery of the lead compound provides an important step toward advancing research programs from discovery into subsequent stages of development. While the specific cardiovascular target associated with the latest compound remains undisclosed, the milestone demonstrates continued progress within the collaboration’s multi-program research strategy.
Advertisement
Atrium Builds Precision Cardiology Pipeline
Beyond its collaboration with BMS, Atrium is advancing its own pipeline of precision cardiovascular RNA therapeutics. The company recently received FDA clearance for the Investigational New Drug application for ATR 1072, its first precision cardiology program targeting PRKAG2 syndrome, a rare genetic cardiac disease. ATR 1072 is entering clinical development through the Corventis Phase 1/2 clinical trial, representing an important transition for Atrium from research into human clinical testing. Atrium’s pipeline also includes ATR 1086, which is being developed for phospholamban (PLN) cardiomyopathy, along with two undisclosed research programs targeting rare cardiomyopathies. The company’s platform was originally designed at Avidity Biosciences and is intended to address challenges associated with delivering RNA therapeutics to specific tissues. By combining targeted delivery technologies with RNA-based mechanisms, Atrium aims to selectively interfere with disease-driving molecular pathways while limiting nonspecific tissue exposure.
The latest $15 million BMS milestone payment therefore represents more than a financial achievement for Atrium Therapeutics. It reflects continued advancement of a collaborative research program focused on applying RNA therapeutics to cardiovascular medicine. As Atrium progresses its independent pipeline and BMS-supported programs, the company is positioning targeted RNA delivery as a potential therapeutic strategy for genetically driven cardiomyopathies and other serious cardiovascular conditions. Further clinical and regulatory development will be required to determine whether these investigational programs can demonstrate safety and efficacy in patients. However, the latest milestone underscores growing industry interest in RNA-based cardiovascular therapies, particularly approaches designed to deliver precision medicines directly to the heart.
Source: Atrium Therapeutics, Bristol Myers Squibb press release
